Palmitylethanolamide

Endocannabinoid

Endogenous cannabinoid. Weak ligand of ${\rm CB_1}$ (${\rm K_i}$ =23.8µM) and ${\rm CB_2}$ (${\rm K_i}$ =13.9µM) receptor. Inhibits fatty acid amide hydrolase (FAAH) (${\rm IC_{50}}$ =5.1µM). Immunosuppressant, anti-inflammatory, anti-nociceptive and anti-convulsant *in vivo*. The exact mode of action has not yet been revealed. It has been suggested that PEA: i) binds to a yet to be discovered cannabinoid receptor similar to ${\rm CB_2}$; ii) administered *in vivo* elicits the synthesis of endogenous agonists of ${\rm CB_2}$; iii) acts as an "entourage" compound by enhancing the activity and/or by influencing the turnover of endogenous agonists of ${\rm CB_2}$, possibly but not uniquely, by inhibiting their degradation.

Citations: 10

View Online »

Ordering Information


Order Online »

BML-FA018-0050

50mg

Manuals, SDS & CofA

View Online »



Handling & Storage

Use/Stability As indicated on product label or CoA when stored as recommended. Stable for at least

1 year after receipt when stored, as supplied, at 0-4°C. Stock solutions are stable for up

to 3 months at -20°C.

Long Term Storage +4°C

Shipping Ambient Temperature

Regulatory Status RUO - Research Use Only

Product Details

Alternative Name PEA, Palmidrol

Appearance White solid.

CAS 544-31-0

Couple Target Cannabinoid receptor, FAAH

Couple Type Inhibitor, Ligand

Formula $C_{18}H_{37}NO_2$

MW 299.5

Purity ≥98% (TLC)

Soluble in DMSO or 100% ethanol.